EFFICACY AND TOXICITY OF CARBOPLATIN/PACLITAXEL BASED CHEMORADIATION FOR LOCALIZED OESOPHAGEAL CANCER
AbstractBackground: The management of Oesophageal and Gastroesophageal junction cancers is challenging. Multimodality therapy with carboplatin/paclitaxel based chemoradiation (CRT) and surgery shows improved efficacy. In this study, we wanted to establish the efficacy and safety of CRT for neoadjuvant and radical treatment of localized oesophageal cancer. Methods: Patients with oesophageal cancer, registered between September 2013 and October 2014 were reviewed retrospectively. Toxicity and efficacy analysis in the form of radiological response rate, R0 resection rate, Progression free survival (PFS) and overall survival (OS) was performed on 102 patients who received radical carbo/pacli induction chemotherapy followed by CRT. Impact of Surgery was seen on PFS and OS. Results: Males and females were 71 (51.1%) and 68 (48.9%) respectively, with squamous cell carcinoma being the predominant histology (92%). Majority of patient belonged to T3/4 and N1 stage. Grade III/IV thrombocytopenia, neutropenia, anaemia, febrile neutropenia requiring hospitalisation, non-hematologic toxicities were noted in 13 (12.8%), 18 (17.7%), 18 (17.7%), 1 (1%), 1 (1%), patients respectively. Complete Radiological response, partial response, Stable disease, progressive disease was seen in 6 (5.9%), 51 (50%), 23 (22.5%) 8 (8.7%), respectively. Resection was done in 29 (28.4%). Complete and partial pathological response were seen 19 (65.5%), 10 (34.4%), respectively. PFS at 40 and 80 weeks was 90%, 73%, respectively and OS at 80 weeks was 86%. PFS at 40 and 80 weeks was 100% and 90.5%, respectively with resection, while it was 86% and 65%, without resection (P value 0.015). OS at 40 and 80 weeks was 100% (both) with resection, while it was 96% and 79.5% weeks without resection. (p-value 0.034). Conclusions: Carbo/pacli based CRT is effective with acceptable toxicity profile in treating localised oesophageal cancer as both as Radical CRT and as a part of multimodality therapy. For definitive results, long term follow up and prospective analysis are required.Keywords: Oesophageal neoplasms; Chemoradiotherapy; Survival; Toxicity
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for Esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20(5):1167–74.
Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW. An evaluation of Prognostic factors and tumor staging of Resected carcinoma of the esophagus. Ann Surg 2007;245(5):717–25.
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090–8.
Cooper JS, Guo MD, Herskovic A, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced Esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281(17):1623–7.
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and Radiotherapy compared with Radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593–8.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of Trimodality therapy with Cisplatin, Fluorouracil, Radiotherapy, and surgery compared with surgery alone for Esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086–92.
Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638–43.
Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993;71(2):493–509.
Yildirim M, Parlak C, Sezer C, Eryilmaz R, Kaya C, Yildiz M. Coronary Vasospasm secondary to 5-Fluorouracil and its management: Case report. Eurasian J Med 2011;43(1):54–6.
Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98(10):2177–83.
Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of Preoperative Chemoradiation in patients with localized gastric Adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24(24):3953–8.
Honing J, Smit JK, Muijs CT, Burgerhof JGM, Paardekooper G, Muller K, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638–43.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional cancer. N Engl J Med 2012;366(22):2074–84.
Oncology Endpoints in a Changing Landscape. Manag Care 2016;1(suppl):1–12.